Huons launches 'Vegicote'... Enters chronic disease cystitis market
Hyaluronic Acid + Chondroitin Sulfate Complex
Protects Damaged GAG Layer in Bladder, Provides 'Pain Relief' Effect
[Asia Economy Reporter Lee Gwanju] Huons is making a full-scale entry into the chronic disease cystitis market.
On the 20th, Huons announced the launch of 'Vesicot,' a tissue repair biomaterial that is a mixed formulation of hyaluronic acid and chondroitin sulfate.
Vesicot is a class 4 medical device designed to alleviate cystitis symptoms and improve pain in patients with chronic recurrent and interstitial cystitis and bladder pain syndrome. It contains a mixture of hyaluronic acid and chondroitin sulfate, the main components of the bladder mucosal tissue (GAG) layer, which supplements the GAG layer damaged by inflammation, relieves pain, and protects the bladder wall from external irritants such as urine and waste products.
Cystitis has a high recurrence rate and tends to develop into a chronic condition. It occurs more frequently in women due to anatomical reasons, especially in women over their 50s after menopause when estrogen secretion decreases. However, due to the nature of urological diseases, many hesitate to visit hospitals, resulting in delayed diagnosis and worsening of the condition.
Hot Picks Today
"Stock Set to Double: This Company Smiles Every...
- "Continuous Groundwater Extraction Causes Mexico City of 22 Million to Sink by 2...
- “Did They Bet Too Early?” Losses Snowball for ‘Geopverse Ants’ as KOSPI Soar...
- "Going to Seongsu-dong?" Japanese Girl Group Faces Taxi Refusal in Seoul
- "Prime Minister in Underwear?"... Italy's Meloni Posts Herself to Warn of Deepfa...
A Huons official stated, “Interstitial cystitis (IC) and bladder pain syndrome (BPS) occur for various reasons such as bacterial infection, immune deficiency, stress, and hormonal abnormalities. They are accompanied by pain such as dysuria and pelvic pain, and irritative urinary symptoms such as frequent urination and urgency, which reduce daily concentration and quality of life. Therefore, it is necessary to improve symptoms with appropriate treatment methods.” He added, “Vesicot is expected to expand the choices for cystitis patients and medical professionals in the cystitis medical device market and become a treatment that will grow the domestic cystitis treatment market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.